📊 FNCH Key Takeaways
Is Finch Therapeutics Group, Inc. (FNCH) a Good Investment?
Finch Therapeutics is in severe financial distress with zero revenue, massive operating losses of $11.3M, and negative free cash flow of $9.1M despite holding $16M in cash. The company is burning through its cash reserves at an unsustainable rate with no demonstrated revenue-generating capability, and at current burn rates will exhaust its cash within approximately 1.8 years.
Finch Therapeutics shows very weak fundamentals: revenue has fallen to zero, losses remain significant, and operating cash flow is deeply negative. While the balance sheet is helped by $16.04M in cash, a 3.87x current ratio, and no long-term debt, the business currently lacks operating traction and is consuming capital without evidence of sustainable growth.
Why Buy Finch Therapeutics Group, Inc. Stock? FNCH Key Strengths
- Strong liquidity position with $16M cash and 3.87x current ratio provides near-term runway
- No long-term debt eliminates financial distress risk from leverage
- EPS improved 35.4% YoY indicating reduced share dilution or loss reduction on per-share basis
- No long-term debt reduces financial leverage risk
- Liquidity is still solid with $16.04M cash and a 3.87x current ratio
- Balance sheet remains positive with $14.22M in stockholders' equity
FNCH Stock Risks: Finch Therapeutics Group, Inc. Investment Risks
- Zero revenue with 87.6% YoY decline indicates failed commercialization or product-market fit issues
- Operating cash burn of $9.1M against $16M cash reserves indicates 1.8-year runway without revenue generation
- Negative ROE of -61.3% and ROA of -19.1% demonstrate severe value destruction for shareholders
- No insider buying activity in past 90 days suggests management lacks confidence in turnaround
- Biopharmaceutical company model typically requires multi-year development; inability to generate revenue after presumably reaching that stage is critical failure
- Revenue declined 87.6% year over year to zero, indicating severe commercial deterioration
- Persistent losses with -$11.31M operating income and -$9.09M operating cash flow point to an unsustainable business model
- Negative ROE and ROA suggest poor capital efficiency and ongoing erosion of shareholder value
Key Metrics to Watch
- Quarterly cash balance and burn rate trajectory
- Progress toward regulatory approval or commercial partnerships
- Operating cash flow trends and path to profitability timeline
- Cash runway and quarterly operating cash burn
- Any recovery in revenue or pipeline-driven monetization
Finch Therapeutics Group, Inc. (FNCH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.87x current ratio provides a solid financial cushion.
FNCH Profit Margin, ROE & Profitability Analysis
FNCH vs Healthcare Sector: How Finch Therapeutics Group, Inc. Compares
How Finch Therapeutics Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Finch Therapeutics Group, Inc. Stock Overvalued? FNCH Valuation Analysis 2026
Based on fundamental analysis, Finch Therapeutics Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Finch Therapeutics Group, Inc. Balance Sheet: FNCH Debt, Cash & Liquidity
FNCH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Finch Therapeutics Group, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-72.12 indicates the company is currently unprofitable.
FNCH Revenue Growth, EPS Growth & YoY Performance
FNCH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | N/A | -$3.9M | $-3.01 |
| Q1 2024 | N/A | -$3.9M | $-2.41 |
| Q3 2023 | N/A | -$2.4M | $-1.51 |
| Q2 2023 | N/A | -$7.0M | $-4.33 |
| Q1 2023 | $107.0K | -$24.6M | $-0.52 |
| Q3 2022 | $138.0K | -$10.0M | $-0.21 |
| Q2 2022 | $361.0K | -$14.0M | N/A |
| Q1 2022 | $354.0K | -$14.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Finch Therapeutics Group, Inc. Dividends, Buybacks & Capital Allocation
FNCH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Finch Therapeutics Group, Inc. (CIK: 0001733257)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FNCH
What is the AI rating for FNCH?
Finch Therapeutics Group, Inc. (FNCH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FNCH's key strengths?
Claude: Strong liquidity position with $16M cash and 3.87x current ratio provides near-term runway. No long-term debt eliminates financial distress risk from leverage. ChatGPT: No long-term debt reduces financial leverage risk. Liquidity is still solid with $16.04M cash and a 3.87x current ratio.
What are the risks of investing in FNCH?
Claude: Zero revenue with 87.6% YoY decline indicates failed commercialization or product-market fit issues. Operating cash burn of $9.1M against $16M cash reserves indicates 1.8-year runway without revenue generation. ChatGPT: Revenue declined 87.6% year over year to zero, indicating severe commercial deterioration. Persistent losses with -$11.31M operating income and -$9.09M operating cash flow point to an unsustainable business model.
What is FNCH's revenue and growth?
Finch Therapeutics Group, Inc. reported revenue of $0.0.
Does FNCH pay dividends?
Finch Therapeutics Group, Inc. does not currently pay dividends.
Where can I find FNCH SEC filings?
Official SEC filings for Finch Therapeutics Group, Inc. (CIK: 0001733257) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FNCH's EPS?
Finch Therapeutics Group, Inc. has a diluted EPS of $-5.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FNCH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Finch Therapeutics Group, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FNCH stock overvalued or undervalued?
Valuation metrics for FNCH: ROE of -61.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FNCH stock in 2026?
Our dual AI analysis gives Finch Therapeutics Group, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FNCH's free cash flow?
Finch Therapeutics Group, Inc.'s operating cash flow is $-9.1M, with capital expenditures of $0.0.
How does FNCH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -61.3% (avg: 15%), current ratio 3.87 (avg: 2).